When a pharmaceutical, biotech, or medical device company brings a product to market in the United States or the European Union, the regulatory dossier is only as strong as its weakest document. A trial protocol, an informed consent form, a clinical study report, or a label can be scientifically impeccable and still trigger a deficiency letter or an information request simply because the translation was inaccurate, inconsistent, or unsupported by the right certification. For Israeli sponsors, contract research organizations, and manufacturers exporting to these markets, understanding the translation expectations of the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is not a clerical detail. It is part of the regulatory strategy itself.
The two agencies approach language very differently, and conflating their requirements is a common and costly mistake. The FDA operates in a single official language and tends to focus on whether foreign-language source data can be trusted. The EMA operates across twenty-four official EU languages and imposes highly structured linguistic obligations at the point of authorization. This article maps out what each agency expects, where translation quality is formally assessed, and how an Israeli organization working with the Ministry of Health, the courts, or international partners should prepare its documentation.
What the FDA Expects: English, Accuracy, and Source Verification
The FDA conducts its review in English. Title 21 of the Code of Federal Regulations is explicit that submissions and any foreign-language material accompanying them must include an accurate and complete English translation, and the original foreign-language document must be retained and made available on request. This applies across the spectrum of submissions, including Investigational New Drug applications, New Drug Applications, Biologics License Applications, and the various device pathways such as premarket notification and premarket approval. The agency is not interested in elegant prose. It is interested in whether the English version faithfully represents the source.
Two practical principles follow. First, the translation of a scientific or clinical document must preserve technical meaning without interpretation or smoothing. A mistranslated adverse event term, dosing unit, or inclusion criterion can distort the safety and efficacy picture the reviewer is building. Second, the FDA increasingly scrutinizes foreign clinical data, especially trials conducted outside the United States that are offered as pivotal evidence. Reviewers and inspectors may compare the submitted English translation against original case report forms, source records, and consent documents. Any discrepancy between the translated dossier and the underlying source data can raise data integrity concerns that go well beyond language.
For this reason, FDA-facing translations should be performed by qualified translators with genuine subject matter competence, accompanied by a signed statement of accuracy from the translator or agency, and kept under a documented quality process. A certificate that names the translator, attests to completeness and fidelity, and is traceable to the source document is the practical standard that withstands scrutiny during review and inspection.
What the EMA Expects: Twenty-Four Languages and the QRD Process
The EMA presents a fundamentally different challenge because authorization in the European Union is multilingual by design. Under the centralised procedure, a marketing authorization granted by the European Commission is valid across all member states, and the product information must be available in all official EU languages plus Icelandic and Norwegian. The product information comprises the Summary of Product Characteristics, the labelling, and the package leaflet, the documents that physicians, pharmacists, and patients ultimately rely on.
These documents are not translated freely. They follow the Quality Review of Documents (QRD) templates maintained by the EMA, which fix the structure, headings, and standard statements that must appear in every language. The translation process is tightly scheduled around the opinion of the Committee for Medicinal Products for Human Use. The applicant submits an English master, the QRD group and member states review the linguistic versions, and the applicant must address comments within strict deadlines before the Commission decision. Errors at this stage delay launch in the affected markets and can ripple across the entire authorization timeline.
User testing adds a further layer for the package leaflet. EU legislation requires that the leaflet be readable and comprehensible to patients, often demonstrated through formal readability testing. A translation that is technically correct but reads awkwardly, uses inconsistent terminology, or fails to convey instructions clearly can undermine that comprehensibility requirement. Consistency across all language versions, alignment with the approved English text, and adherence to established EU pharmaceutical terminology are therefore not stylistic preferences. They are conditions of compliance.
Documents Where Translation Quality Carries the Most Risk
Across both agencies, certain document classes concentrate the linguistic risk. Informed consent forms must be comprehensible to the actual participant population, which in multinational trials means careful, ethics-committee-approved translations rather than improvised renderings. Clinical study reports and protocols carry dense methodology and safety terminology where a single mistranslated qualifier can alter meaning. Investigator brochures, manufacturing and quality sections, and pharmacovigilance documents such as periodic safety reports all combine regulatory weight with technical precision.
Labelling and patient-facing materials sit in a category of their own because they are read by people making medical decisions. Dosage, contraindications, warnings, and storage instructions leave no room for ambiguity. The recurring theme is that translation in this field is a controlled process, not a one-off task. It relies on validated terminology, translation memories that enforce consistency across a product family, a second independent reviewer, and a clear audit trail showing who translated, who checked, and against which source version.
The Israeli Context: ITA, Apostille, and Bilingual Source Material
Israeli life sciences organizations face a specific set of conditions. Source documentation frequently exists in Hebrew, including ethics committee (Helsinki Committee) approvals, investigator credentials, site agreements, and regulatory correspondence with the Israeli Ministry of Health. When these documents support a submission to the FDA or feed into an EMA dossier, they require accurate translation into English, and corporate or official documents may also need legalization. Where a foreign authority requests authentication of an Israeli public document, the apostille issued under the Hague Convention, handled in Israel through the courts and the Ministry of Foreign Affairs, is the standard route, and a certified translation often accompanies it.
The Israel Tax Authority (ITA) is relevant in a different sense. Cross-border regulatory and commercial activity, licensing arrangements, transfer of intellectual property, and the financial structuring behind a global submission generate documentation that must satisfy both regulatory and tax scrutiny. Contracts, financial statements, and corporate records that travel between Israeli and foreign authorities benefit from professional translation that keeps legal and financial terminology consistent across versions, reducing the risk of challenge from either a regulator or a tax authority.
The practical takeaway is straightforward. Treat translation as a planned workstream within the regulatory project, not an afterthought at submission. Decide early which documents need certified translation and which need apostille, lock your source versions before translation begins, use translators with real medical and regulatory expertise rather than general linguists, and maintain a certificate and audit trail for every translated document. Doing so protects the submission timeline, preserves data integrity, and keeps the dossier defensible if a reviewer, an inspector, or a court ever asks how the words on the page came to be.